Cargando…
The relationship between PARP inhibitors with the relapse and leukemisation of lymphomas: a case report
BACKGROUND: Nowadays the poly-ADP ribose polymerase inhibitors (iPARPs) are the mainly treatment for the ovarian cancer and other solid tumours. However, given its recent use, long-term toxicity is still under study. The occurrence of acute leukaemias and myelodysplastic syndromes (MDS) secondarily...
Autores principales: | Navalón-Jiménez, Marta, Olivares-Hernández, Alejandro, Figuero-Pérez, Luis, Miramontes-González, José Pablo, Montero-Mateos, Enrique, Cruz-Hernández, Juan Jesús, Fonseca-Sánchez, Emilio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130682/ https://www.ncbi.nlm.nih.gov/pubmed/37122963 http://dx.doi.org/10.21037/acr-22-91 |
Ejemplares similares
-
Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2021) -
Dopamine Receptors and the Kidney: An Overview of Health- and Pharmacological-Targeted Implications
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2021) -
Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments—a systematic review
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2023) -
Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2021) -
Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data
por: Toribio-García, Irene, et al.
Publicado: (2023)